Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients: A Randomized Placebo-Controlled Clinical Trial.

Line Aas Mortensen Bente Jespersen Anne Sophie Lind Helligsoe Birgitte TougaardDonata Cibulskyte-NinkovicMartin EgfjordLene Boesby Niels MarcussenKirsten MadsenBoye L JensenInge PetersenClaus Bistrup Helle C Thiesson

Published in: Clinical journal of the American Society of Nephrology : CJASN (2024)

Spironolactone added to standard therapy for three years in kidney transplant patients did not improve kidney function, long-term proteinuria or interstitial fibrosis.

Keyphrases

clinical trial
end stage renal disease
double blind
ejection fraction
chronic kidney disease
newly diagnosed
placebo controlled
phase ii
study protocol
prognostic factors
squamous cell carcinoma
patient reported outcomes
phase iii
open label
patient reported
phase ii study
rectal cancer